Immunocore to present at upcoming investor conferences

Rhea-AI Summary

Immunocore Holdings Plc (Nasdaq: IMCR) announced presentations at key investor conferences in February 2023. The conferences include the Guggenheim Oncology Conference on February 8, SVB Securities Global Biopharma Conference on February 16, and Citi's 2023 Virtual Oncology Leadership Summit on February 22. Each session will feature a fireside chat and will be webcast live. Immunocore specializes in developing T cell receptor (TCR) bispecific immunotherapies for various diseases, including cancer and autoimmune conditions. The company’s flagship therapy, KIMMTRAK, is approved for treating certain types of uveal melanoma.

Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 February 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune, and infectious diseases, today announced that management will present at the following investor conferences in February:

• Guggenheim Oncology Conference
  Fireside Chat: Wednesday, February 8, 2023, at 11:20 a.m. ET
  

• SVB Securities Global Biopharma Conference
  Fireside Chat: Thursday, February 16, 2023, at 2:20 p.m. ET
  

• Citi's 2023 Virtual Oncology Leadership Summit
  Fireside Chat: Wednesday, February 22, 2023, at 12:00 p.m. ET
  

The presentations will be webcast live and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentations will be made available for a limited time.

##

About Immunocore

Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune, and infectious disease. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.

CONTACT: 

Immunocore
Sébastien Desprez, Head of Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/ Chris Welsh/Jessica Hodgson
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

Investor Relations  
Clayton Robertson, Head of Investor Relations
T: +1 215-384-4781
E: ir@immunocore.com

FAQ

When is Immunocore's presentation at the Guggenheim Oncology Conference?

Immunocore will present at the Guggenheim Oncology Conference on February 8, 2023, at 11:20 a.m. ET.

What is the date of Immunocore's participation in the SVB Securities Global Biopharma Conference?

Immunocore's participation in the SVB Securities Global Biopharma Conference is scheduled for February 16, 2023, at 2:20 p.m. ET.

What will be discussed at Immunocore's fireside chat during the Citi's 2023 Virtual Oncology Leadership Summit?

Immunocore's fireside chat at Citi's 2023 Virtual Oncology Leadership Summit will take place on February 22, 2023, at 12:00 p.m. ET, focusing on their immunotherapy developments.

How can I watch the Immunocore presentations?

The Immunocore presentations will be webcast live and can be accessed in the 'Investors' section of Immunocore's website.

What is KIMMTRAK, developed by Immunocore?

KIMMTRAK is Immunocore's advanced TCR therapeutic approved for treating HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.